- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03875560
IC14 in Adult Patients With Dengue Fever
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Safety, Pharmacokinetic, Pharmacodynamic and Preliminary Efficacy Study of IC14 in Adult Patients With Dengue Fever
Study Overview
Detailed Description
The study will be conducted in two parts and will include an open label phase of a single dose of IC14 (Part A) and a randomized phase of multiple doses of IC14 and placebo (Part B). Up to 52 patients will be enrolled in both parts of the study.
Part A will consist of 12 patients given one of three doses of IC14 as a single dose open-label . Each patient must complete 14 days before the enrollment of subsequent patients. Part A subjects will be hospitalized for 4 days. During and at the end of 4-day admission to the clinical research unit, and on Study Days 5, 6, 7, 14, 21 and 32, Part A patients will have their health status assessed. The last subject in Part A must complete 32 days of participation before Part B of the trial is opened.
Part B consists of 40 patients randomized equally to one of 4 dosing regimens which will include a single dose or multiple doses of IC14 or placebo given at different dosing frequencies. In Part B, Cohort 1 and 2 subjects (single dose) will be inpatient for 4 days and Cohort 3 and 4 subjects (four daily doses) will be inpatient for 5 days. During and at the end of the admission to the clinical research unit, and on Study Days 5, 6, 7, 14, 21 and 32, Part B patients will have their health status assessed.
Study Type
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Fever > 38°C for < 48 hours and clinical presentation consistent with dengue fever.
- Positive NS1 strip assay or reverse-transcriptase polymerase chain reaction (RT-PCR) assay for dengue virus.
- Informed consent form signed and dated by the patient.
- Subject able to give informed consent and able to comply with all study visits and all study procedures.
Females of childbearing potential should be using and committed to continue using acceptable birth control methods.
- Sexual abstinence (inactivity) for 1 month prior to screening through study completion; or
- Intrauterine device (IUD) in place for at least 3 months prior to study through study completion; or
- Stable hormonal contraception for at least 3 months prior to study through study completion; or
- Surgical sterilization (vasectomy) of male partner at least 6 months prior to study.
- To be considered of non-childbearing potential, females should be surgically sterilized (bilateral tubal ligation, hysterectomy, or bilateral oophorectomy at least 2 months prior to study) or be post-menopausal and at least 3 years since last menses.
Exclusion Criteria
One or more of the following dengue warning signs and symptoms:
- Intense and continuous abdominal pain (referred pain or on palpation);
- Persistent vomiting;
- Fluid accumulation (ascites, pleural effusion, or pericardial effusion);
- Postural hypotension and/or collapse;
- Painful hepatomegaly > two centimeters below the right costal margin;
- Mucosal bleeding;
- Major bleeding (hematemesis and/or melena);
- Lethargy and/or irritability;
- Diminished urine output;
- Hypothermia;
- Progressive increase in hematocrit or 20% above baseline or normal for age;
- Abrupt drop in platelets;
- Respiratory discomfort.
One or more of the following signs and symptoms of severe dengue, such as:
- Severe plasma extravasation, leading to shock evidenced by one or more of the following:
- Tachycardia;
- Cold distal extremities;
- Weak, thready pulse;
- Slow capillary refill (> 2 seconds);
- Pulse pressure < 20 mmHg;
- Tachypnea; or
- Oliguria (<1.5 mL/kg/hr).
- Systolic blood pressure < 90 mmHg or decrease >40 mmHg;
- Cyanosis;
- Fluid accumulation with respiratory discomfort;
- Severe bleeding; or
- Severe organ impairment, evidenced by one or more of the following:
- Liver impairment (AST >1000 U/L, international normalized ratio >1.5);
- Renal impairment (serum creatinine ≥1.5 mg/dL); or
- Myocarditis, pericarditis, or clinical heart failure (by chest x-ray, echocardiography, electrocardiogram, or cardiac enzymes if available).
- Female who is pregnant, lactating or of childbearing potential.
- Self-reported or suspected congenital or acquired immunodeficiency (including HIV infection); or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the previous 3 months).
- Prior vaccination against dengue fever.
- Significant chronic illness that, in the opinion of the Investigator, would interfere with study validity, conduct or completion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: FACTORIAL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Part A/Single Dose
IC14 0.5, 1.0 or 2.0 mg/kg IV as a single dose (subjects are assigned and not randomized to this arm.
When Part A is complete, Enrollment to Part B will commence).
|
recombinant chimeric anti-human CD14 monoclonal antibody
|
EXPERIMENTAL: Part B/Cohort 1
IC14 4 mg/kg/day IV or placebo IV x 1 day.
|
Inactive
recombinant chimeric anti-human CD14 monoclonal antibody
|
EXPERIMENTAL: Part B/Cohort 2
IC14 8 mg/kg/day IV or placebo IV x 1 day.
|
Inactive
recombinant chimeric anti-human CD14 monoclonal antibody
|
EXPERIMENTAL: Part B/Cohort 3
IC14 2 mg/kg/day IV x 1 day followed by IC14 1 mg/kg/day IV x 3 days or placebo IV daily for 4 days.
|
Inactive
recombinant chimeric anti-human CD14 monoclonal antibody
|
EXPERIMENTAL: Part B/Cohort 4
IC14 4 mg/kg/day IV x 1 day followed by IC14 2 mg/kg/day IV x 3 days or placebo IV daily for 4 days.
|
Inactive
recombinant chimeric anti-human CD14 monoclonal antibody
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of treatment-emergent adverse events (safety, tolerability)
Time Frame: 32 days
|
Number of patients with treatment-related adverse events as classified according to MedDRA
|
32 days
|
Area under the curve of IC14 serum concentration
Time Frame: 14 days
|
Area under the curve of IC14 serum concentration
|
14 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dengue viral load
Time Frame: 32 days
|
Impact of treatment on dengue viral load measured by quantitative viral load and plasma NS1 viral protein
|
32 days
|
Fever
Time Frame: 32 days
|
Impact of treatment on duration of fever
|
32 days
|
Dengue symptom score
Time Frame: 32 days
|
Impact of treatment on dengue symptom severity (0 normal] to 24 [worst])
|
32 days
|
Disease severity
Time Frame: 32 days
|
Impact of treatment on duration of hospitalization; incidence and duration of intensive care unit admission; and incidence of progression to dengue with warning signs or severe dengue
|
32 days
|
Mortality
Time Frame: 32 days
|
Impact of treatment on survival
|
32 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EDF-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dengue Fever
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseaseVietnam
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseasesPeru
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseasesSingapore
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseasesMexico
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic FeverSingapore
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseasesThailand
-
Sanofi Pasteur, a Sanofi CompanyUnited States Department of DefenseCompletedDengue | Dengue Fever | Dengue Hemorrhagic FeverUnited States
-
U.S. Army Medical Research and Development CommandGlaxoSmithKlineCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Shock SyndromePuerto Rico
-
SanofiCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue VirusUnited States
-
SanofiCompletedDengue | Dengue Fever | Dengue Hemorrhagic Fever | Dengue VirusAustralia
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States